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individuals
Kerstin Hoppe1,*, Guido Hack2,*, Frank Lehmann–Horn2, Karin Jurkat–Rott2, Scott Wearing3, 
Alberto Zullo4,5, Antonella Carsana5 & Werner Klingler2,6
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle metabolism which is 
characterized by generalized muscle rigidity, increased body temperature, rhabdomyolysis, and severe 
metabolic acidosis. The underlying mechanism of MH involves excessive Ca2+ release in myotubes 
via the ryanodine receptor type 1 (RyR1). As RyR1 is also expressed in B–lymphocytes, this study 
investigated whether cellular metabolism of native B–lymphocytes was also altered in MH susceptible 
(MHS) individuals. A potent activator of RyR1, 4–chloro–m–cresol (4-CmC) was used to challenge native 
B-lymphocytes in a real–time, metabolic assay based on a pH–sensitive silicon biosensor chip. At the 
cellular level, a dose–dependent, phasic acidification occurred with 4–CmC. The acidification rate, an 
indicator of metabolic activation, was significantly higher in B–lymphocytes from MHS patients and 
required 3 to 5 fold lower concentrations of 4–CmC to evoke similar acidification rates to MHN. Native 
B–lymphocytes from MHS individuals are more sensitive to 4–CmC than those from MHN, reflecting a 
greater Ca2+ turnover. The acidification response, however, was less pronounced than in muscle cells, 
presumably reflecting the lower expression of RyR1 in B–lymphocytes.
In skeletal muscle, Ca2+ is released from the sarcoplasmic reticulum via the ryanodine receptor protein (RyR1) 
and mediates crossbridge cycling of contractile filaments. Activation of myosin ATP–ase requires energy, which is 
replenished by glycolysis and cellular respiration, the latter of which leads to accumulation of acidic metabolites. 
Volatile anesthetics are potent activators of abnormal RyR1. In genetically predisposed individuals, these drugs 
can trigger life–threating hypermetabolic events known as malignant hyperthermia (MH). In such cases, undue 
activation of muscle metabolism causes muscle rigidity, hyperthermia, and severe acidosis1–3. Given the high 
mortality rate associated with the syndrome, it is particularly important to identify MH susceptibility.
Diagnosis of MH is currently based on the in vitro contracture test (IVCT) used by the European malignant 
hyperthermia group or the caffeine halothane contracture test (CHCT) used by the North American malignant 
hyperthermia group, in which surgically excised muscle develops contractures on exposure to select chemicals 
as an indirect marker of myoplasmic Ca2+–concentration4. In many cells, other than skeletal muscle, Ca2+ plays 
an important role as a secondary messenger and activator of cellular processes and its intracellular concentra-
tion is regulated strictly in the range of 10−9 to 10−3 molar. RyR1 is expressed in the membranes of internal Ca2+ 
stores of B–lymphocytes, where cell proliferation, gene expression, antibody secretion, and cytokine production 
are influenced by Ca2+ levels5,6. Indeed, cultured or immortalized B–lymphocytes from MH susceptible (MHS) 
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patients have been shown to have a heightened sensitivity to RyR1 activators compared to MH-negative patients 
(MHN) and to exhibit an increased production of the endogenous pyrogen IL–1β 7,8.
Previously, we have shown with the use of a highly sensitive proton biosensor assay, that MHS can be identi-
fied by measuring the cellular acidification rate of both cultivated myotubes and EBV-immortalized lymphoblas-
toid cell lines9,10. Nevertheless, muscle biopsy is an invasive procedure and the immortalization of lymphoblastoid 
cells is a laborious and time consuming method. Therefore, we investigated whether evaluating metabolic activity 
in native B–lymphocytes might offer a future minimally–invasive approach for MH–diagnostics. Here we show 
that agarose trapped native B–lymphocytes display increased cellular acidification in MHS compared to MHN.
Materials and Methods
Patients. A consecutive sample of 23 patients referred to the MH–center (Ulm, Germany) over a 2–year 
period was recruited for the study. Indications for MH testing were; (1) an adverse anesthetic event of the patient 
or a close relative, (2) a family–history of established MH, or (3) chronic isolated creatine kinase elevation. 
Four individuals without suspicion of neuromuscular disease (e.g. MH) served as healthy controls. Participant 
numbers were determined based on previously published acidification rates measured using a similar method 
in myotubules9. Assuming equal group variance, the projected sample was estimated to have sufficient power 
(β = 0.80) to detect an 30% difference in acidification rates between groups at an α level of 0.05.
Ethics approval for this study was obtained from the Ethics Committee of University of Ulm, Germany. 
Informed consent was obtained from patients prior to their participation. All methods were carried out in accord-
ance with the approved guidelines and signed informed written consent was collected from all participants prior 
to participation in the study.
Gene mutation screening was performed on all MHS individuals as described in detail previously10,11. 
Ethylendiamintetraacetate blood samples of fifteen MHS patients were genetically screened for mutations in all 
106 exons of the RyR1 gene and additionally for known mutations of CACNA1S. Blood cells were then haemo-
lysed and DNA extracted and amplified by polymerase chain reaction (PCR) for further analysis. PCR samples 
were mixed with the wild–type amplicons, denatured at 95 °C for 5 min and then cooled at room temperature to 
allow heteroduplexes to form. Amplicons with an altered DHPLC elution profile compared to wild–type ampli-
cons were directly sequenced with dye–terminator chemistry (Applied Biosystems).
Chemicals and Solutions. The following chemicals and solutions were used in experimental measurements. 
Chemicals were ordered from Sigma–Aldrich, Steinheim, Germany, unless stated otherwise. Concentrations have 
been expressed in mM unless noted otherwise:
Krebs–Ringer solution. NaCl 118, KCl 3.4, MgSO4 0.8, KH2PO4 1.2, glucose 11.1, NaHCO3 25.0, CaCl2 2.5, pH 7.4.
Density gradient centrifugation for leukocyte isolation. Ficoll with 1.077 g/ml density (L6115, Biochrom, Berlin, 
Germany), phosphate buffer solution without Ca2+ and Mg2+ (L1825, Biochrom, Berlin, Germany)12.
Cryopreservation. Hanks medium (L2015, Biochrom, Berlin, Germany) with 20% fetal calf serum (F2442, 
Sigma, USA)13.
Thawing of leukocytes. Hanks medium (L2015, Biochrom, Berlin, Germany) with 10% fetal calf serum at 
37 °C, buffered Roswell Park Memorial Institute medium with 26.7 ml/L NaHCO3 (R6504, Sigma, Deisenhofen, 
Germany) and 1% fetal calf serum14.
Isolation solution. Phosphate–buffered saline with and without Ca2+ and Mg2+ supplemented with 0.1% bovine 
serum albumin (BSA) (A2153, Sigma, Deisenhofen, Germany), unbuffered RPMI medium (4.78 ml/L 5 M NaCl, 
osmolarity 280 mOsmol) (R6604, Sigma Deisenhofen, Germany) with 1% fetal calf serum, negative isolation kit, 
(113.13 Dynal, Norway).
Cytosensor test solution. Unbuffered RPMI medium (R6504, Sigma, Deisenhofen, Germany) with 1% fetal calf 
serum, low melt agarose (1.5%) (F50082, FMC, USA) resolved in unbuffered RPMI medium.
Stock solutions of the trigger reagents caffeine and 4–chloro–m–cresol (4–CmC) were prepared in bi–dis-
tilled water. Halothane was applied using a vaporizer (Vapor 19.1, Draeger, Lübeck, Germany). Caffeine was 
purchased from Merck (Darmstadt, Germany), 4–CmC from Fluka (Neu–Ulm, Germany) and halothane from 
Zeneca (Plankstadt, Germany).
IVCT. In accordance with the recommendations of the European Malignant Hyperthermia Group, MHS was 
diagnosed using the in vitro contracture test as described in detail elsewhere4,15. In brief, this test determines 
the contractile sensitivity of surgically excised muscle specimens to halothane and caffeine. Biopsies were taken 
from the vastus lateralis muscle under regional anesthesia. Basal tension and the twitch response to supramax-
imal electrical stimulation (30 to 70 V, 0.2 Hz, 1 ms) was recorded with a force transducer. Muscle bundles from 
MHS patients have lower contractile thresholds to caffeine and halothane than MHN. A positive result for MHS 
was defined as a contracture force of ≥ 2 mN at a caffeine concentration ≤ 2 mM and a halothane concentration 
≤ 2% v/v4. Effects of 4–CmC (concentration range, 25–200 μ M) were also tested on the excised muscles biopsies. 
In addition, biopsies were sent for standard histological examination of core formation, polygonal shape of 
myofibers, nuclear location, fiber type composition and the presence of inflammatory cell infiltrate.
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Isolation of B–lymphocytes. Blood samples (18 ml) from patients referred for an in vitro contracture test 
were also taken for isolation of B–lymphocytes. After Ficoll separation, the remaining leucocytes were tempo-
rarily stored by cryopreservation at − 70 °C. An indirect isolation method was then employed to avoid activation 
of cellular metabolism by direct binding of CD19–antibodies to B–lymphocytes16,17. Leukocytes were incubated 
with a mixture of primary antibodies against CD2, CD7, CD3, CD14, CD16, and CD56 for 20 minutes at 4 °C. In 
a second step, secondary monoclonal antibodies with magnetic beads were conjugated18,19. With application of a 
stationary magnetic field, the B–lymphocytes remained in the supernatant. The cells were then suspended in aga-
rose for the acidification measurements and stimulated with increasing doses of 4–CmC, a potent RyR1 agonist.
Mononuclear cells and EBV-transformed cell lines. Whole blood was collected in EDTA-treated 
tubes and mononuclear cells were isolated by Ficoll-Hypapue density gradient centrifugation. For infection with 
Epstein-Barr virus (EBV), mononuclear cells were exposed to supernatants of the B95.8 cell line according to 
standard procedures20. Cells were cultured in Iscove’s Modified Dulbecco’s Medium (13390, Sigma-Aldrich) sup-
plemented with 20% fetal bovine serum (CH30160,03, Hyclone) and 1%L-glutamine (G7513, Sigma-Aldrich).
Proton release measurements. A cytosensor® microphysiometer (Molecular Devices, San Diego) was 
used to analyze the metabolism of human lymphocytes as described elsewhere9,10. In brief, the device harbors a 
pH–sensitive silicon biosensor which measures changes in the current–voltage relation when protons are released 
into the bath solution. The charged groups originate from a thin insulating layer of silicon oxide and nitride. The 
measuring compartment of the micro–chamber containing the cells had a volume of 1.4 μ l and was perfused dis-
continuously with a weakly buffered culture medium at a rate of 50 μ l/min and a temperature of 37 °C.
Figure 1 shows four consecutive perfusion cycles during which the proton concentration in the chamber equil-
ibrated with that of the bath solution. Cessation of perfusion (i.e. ‘no flow’ interval) results in the accumulation of 
extruded protons from cells within the chamber (i.e. decreased pH), which invokes a reduction in the potential 
difference or decreased voltage at the biosensor. To determine the acidification rate corresponding to the metabolic 
activation of B–lymphocytes, simple linear regression was used to determine the slope of a 30 second interval of 
the voltage–time curve. The chambers were perfused for a minimum of seven minutes between consecutive addi-
tions of trigger substances to ensure equilibration. The amplitude of recorded signals was typically in the order of 
0.01–0.1 pH–units/min. Thus, the timing of the perfusion cycle reflected a compromise between the temporal res-
olution of the measurement and the time required to determine the acidification rate during the ‘no–flow’ interval.
Figure 2 shows the time–resolved change in acidification rate of isolated B–lymphocytes caused by addition of 
300 μ M 4–CmC. Weakly buffered culture medium was pumped discontinuously through the sample volume. Each 
measurement point corresponded to a single pump cycle of the perfusion system. In the ‘no flow’ interval, the pH 
decreased due to cellular proton release. Any stimulus that activated cell metabolism e.g. application of 300 μ M 
4–CmC, resulted in a further change in the slope of the curve, which represented the acidification rate. Control of 
the pump cycle, data acquisition and acidification rate calculation were carried out with the system’s microcomputer 
(Macintosh Power PC 7600/132) and proprietary software (Cytosoft® program, Molecular Devices, San Diego).
4–CmC was chosen for microphysiometry as it is a potent activator of RyR1 mediated Ca2+ release, and exhib-
its 15 times higher affinity for RyR1 compared to caffeine21. Ryanodine was chosen as a second application sub-
stance for evaluation of the microphysiometry method.
Statistical Analysis. StatXact (Version 5, Cytel Software, Cambridge, MA) was used for all statistical pro-
cedures. Shapiro Wilkes tests were used to evaluate data for underlying assumptions of normality. Outcome 
variables were determined to be normally distributed, so means and standard deviations have been used as sum-
mary statistics. Potential differences between groups in acidification rates were evaluated using Wilcoxon Mann 
Whitney test. An alpha level of 0.05 was used for all tests of significance.
Figure 1. Time–resolved determination of the proton secretion rate from native human blood  
B–lymphocytes. Four consecutive pump cycles of the perfusion system and corresponding pH–dependent 
alterations in the change of slope due to the combined action of the proton extrusion from the B–lymphocytes 
and the flow rate of the perfusion system. The voltage within the chamber represents a measurement of the 
proton concentration. During the intervals labelled “pump–on”, the chamber was perfused with experimental 
solution. The “pump–off ” intervals prevent the removal of protons, resulting in a change of the inflection points 
of the tension line. During this interval, the acidification rate was determined from the pH decrease.
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Results
Characterization of individuals. In total, 24 individuals underwent IVCT during the two year study period. 
According to the European IVCT protocol, thirteen were classified as MHS and seven as MHN. Four additional 
patients served as healthy controls. All individuals were genetically independent and not related. Genetic screening 
identified that ten of the thirteen individual’s with MHS possessed a causative RyR1 mutation. Native B-lymphocytes 
of nine MHS, five MHN and four controls were exposed to 4-CmC to measure acidification rate. Within those, a 
Gly–2434–Arg mutation was detected in five patients and an Arg–614–Cys mutation in one other (Table 1). To 
increase test specifity, immortalized B-lymphocytes of three further MHS and two MHN individuals were exposed 
to ryanodine. Within those three different mutations were detected: Cys4664Arg, Arg530His, Arg2163Pro. Age dis-
tribution, gender balance and body mass index (BMI) were comparable between groups. The mean (SD) age in the 
MHS group was 34.6 (17.0) years and 29.2 (10.7) years in the MHN group, while the mean BMI was 23.6 (2.9) and 
23.7 (2.4) years in the MHS and MHN groups, respectively. The presence of increased CK–levels in MHS patients is 
well known; average CK–levels in MHS was 63 U/L compared with 38 U/L in MHN patients. Histological investiga-
tion detected no specific pathological changes and was unable to differentiate between groups.
B–Lymphocyte separation. B–lymphocytes were isolated from 18 ml samples of whole blood. On average 
23.6 ± 10.0 million leukocytes were counted after the density gradient centrifugation using a Neubauer count-
ing chamber. This equates to a cell count of 1311 ± 555 leukocytes/μ L of investigated whole blood, which when 
compared to the published values (450–10100 leukocytes/μ L) was in the lower range of normal22. On average, 
14.7 ± 8.0 million leukocytes were detected after temporary cryopreservation. After negative isolation, 1.8 ± 1.2 
Figure 2. Acidification rates, as determined in Fig. 1, plotted versus time. Numbers 1 to 4 indicate the four 
perfusion cycles shown in B. 4–CmC = 4–chloro–m–cresol.
Mutation
Halothan Coffeine 4-CMC
Threshold 
(mM)
Contraction 
(mN)
Threshold 
(mM)
Contraction 
(mN) Threshold (μM)
Contraction 
(mN)
Acidification 
threshold 
>25% (μM)
MHS 1 Gly-2434-Arg 0,22 3 2 2 50 5 100
MHS 2 Gly-2434-Arg 0,22 2,2 1,5 4,3 not determined not determined 75
MHS 3 Gly-2434-Arg 0,22 4 1.5 3 not determined not determined 150
MHS 4 Arg-614-Cys 0,44 2,6 2 2,5 50 5,5 200
MHS 5 none detected 0,44 2,4 2 2,4 75 3,2 100
MHS 6 Gly-2434-Arg 0,22 2 1 3,8 25 9 25
MHS 7 Gly-2434-Arg 0,44 3,1 1 5,6 75 5,4 50
MHS 8 none detected 0,44 7 2 7 75 2,5 150
MHS 9 none detected 0,22 3,4 1 4,9 25 14,2 50
MHN 1 none > 0,88 1,2 3 1.9 not determined not determined 300
MHN 2 none > 0,88 1,6 32 1 150 0,8 75
MHN 3 none > 0,88 0,2 4 − 1,4 150 − 1,4 300
MHN 4 none > 0,88 0,6 4 0 150 0,8 300
MHN 5 none > 0,88 0,9 3 − 1,6 100 1 300
Table 1.  Table represents the IVCT with halothane and caffeine and the 4-CmC Acidification threshold 
form MHS and MHN individuals. A Gly-2434-Arg mutation was identified in the MHS individual 1, 2, 3, 6 and 
9, an Arg-614-Cys mutation in MHS 4. In MHS 5, 7 and 8 neither a RyR1 mutation nor a CACNA mutation was 
identified.
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million B–lymphocytes (0.10 ± 0.07 million per μ l extant), were transfected in low melt agarose (1.5%) cups 
for measurement of proton release. The number of B–lymphocytes did not differ significantly between groups. 
B–lymphocytes per μ l of whole blood were 0.10 ± 0.07 in the MHS group, 0.10 ± 0.05 in the MHN group 
(Table 2).
4–CmC induced acidification responses in normal and MHS native B–lymphocytes. Figure 3 demon-
strates the acidification–rate responses of B–lymphocytes from a single MHS and MHN patient. The concentration 
of 4–CmC was gradually increased from a minimum value of 25 μ M to 600 μ M. Each drug application consisted 
of a seven minute exposure with the respective concentration and a comparable washout period with 4–CmC–free 
solution. Ordinate of the upper panel shows the change in acidification rate as a percentage of the initial (predrug) 
basal rate. The responses were qualitatively similar, in that a step change in 4–CmC concentration resulted in a rapid, 
MHS
Leukocytes prae 
Cryo-preservation 
(in mio)
Leukocytes after 
Cryo-preservation 
(in mio)
Leukocytes prae  
Cryo-preservation (in %)
B-Lymphocytes 
(in mio)
B-lymphocytes  
(per ml whole blood)
MHS 1 17.8 11.1 64.0 2.7 0.15
MHS 2 19.5 10.5 54.0 1.9 0.11
MHS 3 18.8 11.1 59.0 0.9 0.05
MHS 4 23.3 13.5 58.0 4.5 0.25
MHS 5 27.4 17.3 63.0 2.7 0.15
MHS 6 9.5 5.0 53.0 0.6 0.03
MHS 7 6.2 3.8 61.0 0.4 0.02
MHS 8 30.0 22.3 74.0 2.66 0.015
MHS 9 0.8 0.4 50.0 0.16 0.001
17.0 ± 9.2 10.5 ± 6.4 60.0 ± 6.8 1.8 ± 1.4 0.1 ± 0.7
MHN
 MHN 1 23.0 6.5 28.0 0.66 0.04
 MHN 2 21.1 9.4 44.0 1.8 0.1
 MHN 3 26.0 17.9 68.0 1.16 0.06
 MHN 4 37.0 24.0 64.0 3.1 0.17
 MHN 5 36.0 21.0 58.0 2.0 0.1
28.6 ± 6.6 15.8 ± 6.7 52.0 ± 14.6 1.7 ± 0.8 0.09 ± 0.04
Control
 C 1 38.0 32.4 85,0 3.3 0.18
 C 2 28.5 14.8 52,0 0.72 0.04
 C 3 30.9 17.5 57,0 3.0 0.17
 C4 28.8 23.3 81,0 0.6 0.03
31.6 ± 3.8 22.0 ± 6.7 69.0 ± 14.4 1.9 ± 1.3 0.11 ± 0.07
Table 2. Table represents total amount of isolated Lymphocytes in the MHS, MHN and healthy controls.
Figure 3. Original traces of acidification responses of native B–lymphocytes at increasing 4–chloro–m–
cresol concentrations. Filled circles show the normalized increase in proton secretion rate recorded from a 
malignant hyperthermia susceptible (MHS) patient confirmed by IVCT. The patient was a carrier of the Gly–
2434–Arg mutation. Filled squares depict rate recordings from a malignant hyperthermia–negative (MHN) 
patient confirmed by IVCT.
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though transient, increase in acidification rate. The rate remained elevated above baseline during the time of stimulus, 
although at a lower level than the transient peak, and only decreased below baseline after return of the control solution.
Figure 4 illustrates the total change in acidification rate of MHS and MHN patients. In Fig. 5 the amplitude 
of the transient response on application of 4–CmC is shown. Figure 6 shows the change in baseline rate, meas-
ured immediately before stimulation with 4–CmC. The total change in acidification rate, which comprises the 
amplitude of both the transient increase and baseline, was significantly increased in the MHS group compared 
to the MHN group (15.0% vs. 6.7%, p < 0.05). On average, stimulation of MHS lymphocytes with 4–CmC over a 
range of concentrations (50–400 μ M) resulted in a magnitude shift of the total dose-response curve, which is in 
the order of a twofold increase as compared to MHN reactions. (p < 0.05). In the MHN group, B–lymphocytes 
needed 2–3 times higher concentrations of 4–CmC to reach a similar increase in total acidification rate as MHS. 
Baseline values, however, were not significantly different between groups.
Comparison of IVCT and microphysiometer test results of B–lymphocytes. With IVCT, a con-
tracture force of 2 mN during exposure to a certain concentration of trigger agent (halothane or caffeine) is con-
sidered diagnostic for MHS. All biopsies used for this investigation had shown unambiguous results in IVCT, i.e., 
concentration thresholds for contractures of muscle fiber bundles triggered by halothane or caffeine were either 
normal (MHN, n = 5) or clearly shifted to lower concentrations (MHS, n = 9). In addition, we also measured 
4–CmC–induced force responses in 11 of 14 muscle biopsies. At concentrations of 25 μ M, 4–CmC resulted in con-
tracture forces of 2 mN or above in previously determined MHS positive biopsies (halothane–caffeine challenge). 
MHN biopsies, however, only reached comparable contracture force at concentrations above 150 μ M.
Comparison between individuals revealed a positive association between the strength of the 4-CmC induced 
IVCT response of muscle and the acidification assay of B–lymphocytes (Figs 7 and 8). There was insufficient data, 
however, to calculate a robust receiver operator characteristic curve to compare tests. Consequently, we estimated 
the sensitivity and specificity of the test using an arbitrary cut-off point. The cut-off point was selected under the 
presumption that maximum sensitivity rather than specificity is critical in MHS. Based on our data, we consid-
ered a total acidification rate of > 25% [at 200 μ M 4-CmC] above baseline as a pathological threshold. Using this 
cut-off point, the assay had a sensitivity of 100% and a specificity of 70%.
Ryanodine induced acidification responses in normal and MHS immortalized B-lymphocytes. 
Figure 9 demonstrates the acidification-rate responses of immortalized B-lymphocytes from four MHS and two 
MHN patients. The dose of 2 μ M ryanodine resulted in a less pronounced increase in acidification rate in MHS 
compared to MHN individuals.
Figure 4. Dose dependence of the acidification rate in IVCT–confirmed malignant hyperthermia–negative 
(MHN). Susceptible (MHS) human B–lymphocytes. Increase in acidification rates (percent of pre–drug value) 
plotted as a function of 4–chloro–m–cresol (4–CmC) concentration. Total normalized increase in acidification 
rate. Mean data from nine MHS patients (filled circles) and five MHN (open circles). Error bars show SD; 
asterisks indicate p < 0.05 using the exact Wilcoxon rank sum test.
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Discussion
We have shown previously that the use of a highly sensitive proton biosensor assay, can identify MHS by measur-
ing the cellular acidification rate of both cultivated myotubes and EBV-immortalized lymphoblastoid cell lines9,10. 
In the current study, we investigated whether evaluating metabolic activity in native human B–lymphocytes 
might offer a future minimally–invasive approach for MH–diagnostics. For each test, B-lymphocyte separation 
took approximately 25 minutes and measurement of the 4-CmC induced acidification rate required, on average, 
only 160 minutes. To apply microphysiometry to human blood cells, we recorded extracellular acidification of 
human B–lymphocytes with a sensitive pH–metric biosensor. The acidification rate that occur after exposure to 
each test chemical concentration are calculated and compared to the mean basal acidification rate of the same 
cells prior to exposure to the test chemical. Stimulation of RyR1 causes intracellular Ca2+ mobilization, resulting 
in an increased energy demand, i.e. ATP, which is re–synthesized by the respiratory chain and glycolysis22. The 
main products of this reaction are CO2 and lactic acid, which results in proton secretion from the cell. Similar to 
muscle cells, stimulation of B–lymphocytes caused a phasic and dose-dependent increase in acidification rate9. 
Figure 5. Normalized peak amplitude. Mean data from nine MHS patients (filled circles) and five MHN 
(open circles). Error bars show SD; asterisks indicate p < 0.05 using the exact Wilcoxon rank sum test.
Figure 6. Normalized increase in baseline acidification rate. Mean data from nine MHS patients (filled 
circles) and five MHN (open circles). Error bars show SD; asterisks indicate p < 0.05 using the exact Wilcoxon 
rank sum test.
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The reaction sequence shows an initial transient peak in acidification rate followed by an elevated plateau phase 
for the duration of stimulation. This is a common signal characteristic of acidification measurements after recep-
tor stimulation23. A decrease of intracellular pH level results in the activation of the Na+ /H– exchanger, which in 
turn causes the transient spike within the measurement signal. The subsequent plateau is likely due to a negative 
feedback mechanism of the cell. An increase in Ca2+ in the millimolar range causes an inactivation of RyR1 and 
reuptake of Ca2+ in the sarcoplasmic reticulum24. Moreover, rapid ATP consumption, which is necessary for com-
plete RyR1 activation, seems to be a contributing feature24. Due to the limited temporal resolution of the meas-
uring system and the rapid kinetics of Ca2+ secretion with 4–CmC stimulation, it is likely that peak acidification 
levels of B–lymphocytes were underestimated by the system used in the current study25.
Figure 7. Comparison of contracture tests and acidification assay. Contracture force from the in vitro 
contracture test plotted relative to 4–chloro–m–cresol (4–CmC) concentration. Error bars indicate SD.
Figure 8. Scatter plot of IVCT data and microphysiometer data at given 4–CmC concentrations reflecting 
a supra–threshold drug response (threshold definitions, 25% increase above baseline value of acidification 
rate in the Cytosensor test [ordinate] and 2 mN concentrations force in the IVCT [abscissa]). 
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To the best of our knowledge, this is the first study to reveal the potential of evaluating the risk of 
MH-disposition in human individuals using peripheral blood and independent of underlying RyR1 genetic muta-
tion. Caused by the genetic heterogeneity, a metabolic assay is indispensable for the diagnosis of MH-disposition. 
In this study we advanced previous work of our group showing that MHS myotubes show an abnormal proton 
metabolism and corroborate the recent findings of Bina et al. demonstrating an increased accumulation of adeno-
sine in lymphocytes from MHS patients26. In this study, both the total and peak acidification rate of native B–lym-
phocytes was higher in MHS than MHN patients. Differences between MHS and MHN patients in acidification 
rates were significant at 4–CmC concentrations between 50 and 400 μ M. The greatest difference in acidification 
rate between groups was detected at a 4–CmC concentration of 200 μ M. Higher concentrations caused a nearly 
parallel increase in total acidification rate in both MHS and MHN groups (Fig. 3). Although further research 
is required, this effect might have been due to nonspecific activation of further Ca2+ signaling cascades, such 
as IP3 or the mitochondrial matrix Ca2+ pool17. Previous research has suggested that the IP3 cascade system in 
blood samples was unable to identify MH susceptibility, however recent data suggests that IP3R–mediated Ca2+ 
release might contribute to increased intracellular Ca2+ levels via additional release27. Moreover, the mitochon-
drial matrix comprises a subcellular Ca2+ store which might contribute to accumulation under conditions of 
de–energization28,29. Compared to earlier investigations of acidification rates in cultivated muscle cells, B–lym-
phocytes showed a lower acidification rate at rest and a 5-fold lower secretion reaction after 4–CmC stimulation9. 
This might reflect the lower expression of the RyR1 within the intracellular storage of B–lymphocytes, a lack of 
the interaction of DHP–R/RyR or further Ca2+ signaling cascades8. Interestingly, the 4–CmC induced increase 
in Ca2+ in B–lymphocytes of MHS and MHN were compared using flow cytometry30. Only concentrations of 
4–CmC above 400 μ M resulted in significant differences in calcium levels30. Early findings dating back to 1987 
tentatively suggested altered immune cell function in MH. In due course, flow cytometry showed distinct aberra-
tions in the response of MH-lymphocytes to 4-CmC31. The acidification assay used in the current study requires 
2 to 3 fold lower 4-CmC concentrations for risk evaluation of MH-disposition.
IVCT has been shown to have a high sensitivity (97–99%) and acceptable specificity (approximately 70%) 
which may be increased to 94% by using two trigger substances (halothane and caffeine)4. The standard pro-
tocol of CHCT and IVCT differ in the following points: Most important, IVCT utilizes incremental exposure 
to halothane and requires only investigation of two muscle bundles for each test substance, CHCT utilizes 3% 
halothane and requires three muscle bundles for each test substance32. CHCT was reported to have a sensitivity 
of 97% and a specificity of 78%33. However, evaluation of muscle biopsies with IVCT has been shown by some to 
have high variability. For instance, poor agreement has been reported in 12% of cases when a standardized IVCT 
approach was used by two MH centers to evaluate muscle biopsies from the same patients32. While the halothane 
test was shown to be more accurate and reproducible than the caffeine test, additional application of 4–CmC as 
a stimulant has been shown to increase the specificity of the IVCT test34,35. In a set of exploratory experiments, 
the effects of halothane were investigated in the microphysiometry set up. However, the results were inconsist-
ent, which we attributed to technical difficulties associated with the use of silicon componentry and the volatile 
nature of the drug. To potentially increase test specifity, we investigated ryanodine as another test substance. The 
ryanodine-induced acidification increase, however, was less prounced compared to 4-CmC even though multiple 
testing of B-lymphocytes was performed after immortalization. Similarly, ryanodine testing was approved as an 
additional test agent in IVCT/CHCT, but showed an overlap between MHS and MHN groups36. Although the 
ryanodine contracture test may help diagnose susceptibility to malignant hyperthermia the results showed high 
variability, which might be at least in part be explained by the pharmacological nature of exclusive “open state” 
receptor binding36.
Metabolic activity of muscle is influenced by several individual factors including nutrition, pre–existing dis-
ease, inflammation and hormonal levels e.g. higher thyroxine, cortisol and insulin levels have been detected 
in MHS positive individuals which might impact IVCT test results. However, microphysiometry (acidification) 
is also an indirect measure of Ca2+ release. Therefore, disorders that affect Ca2+ turnover, energy metabolism 
and proton handling have the potential to adversely influence acidification rates determined via this method. 
Moreover, microphysiometry of B–lymphocytes depends on the function of isolated B–lymphocytes from 
the peripheral blood sample. The CD19 + B-cells comprise a heterogeneous cell population which in turn is 
Figure 9. Effect of 2 μM ryanodine on acidification rate in immortalized B-lymphocytes of two MHN and 
three MHS individuals. Multiple measurements (n) for each individual were included. Mutants Arg2163pro 
and Arg530His were significantly (p < 0.05) different form MHN individuals. Error bars show SEM.
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influenced by a number of physiological and pathophysiological conditions. Nonetheless, the findings of the cur-
rent study suggest that microphysiometry of B-lymphocytes may be a useful first line adjunct for the evaluation 
of MH susceptibility.
Mutations of RyR1 or CACNA1S are only detectable in about 50% to 70% of the MH families37. Moreover, 
alternative pathomechanisms, such as changes of cortisol and thyroxine levels or membrane lipid composition, 
are not detected using standard genetic approaches38. Accordingly, genetic screening by DHPLC identified only 
mutations in six of nine MHS individuals diagnosed by IVCT and acidification measurements. Since not all 
amplicons are sequenced with the same efficiency, some may be underrepresented or missed completely resulting 
in undetected variants37. Recently, exome sequencing revealed rare variants of RyR1 and CACNA1S which were 
excluded before using Sanger sequencing39. In three of our nine MHS individuals a mutation was not detected 
by a follow up investigation using Sanger sequencing. Until cost and time-effective next generation sequencing 
is developed for whole genome analysis, the functional approach seems to be a more reliable approach for MHS 
screening40,41. With 106 exons, to date only 34 RYR1 mutations have been described as causative for MH and/or 
central core disease42–45. For the other roughly 400 known RYR1 variants, functional data are still necessary for 
the proof of pathogenicity. At this point a metabolic assay might offer a future perspective. Most notably, the 
required sampling may be processed decentralized. Detection of non RyR1 mediated forms of MH via a metabolic 
assay of lymphocytes, however, remains uncertain. Microphysiometry of B-lymphocytes, as applied in the current 
study, needs to be studied more extensively with multiple underlying genetic variants before it could be clinically 
used as a pre-screening test for MH.
Conclusion
While further research is required, the findings of our study, highlight the potential of metabolic assays of native 
B–lymphocytes from peripheral blood to be used as a pre–screening tool for MHS or as an adjunct to IVCT. 
Native B–lymphocytes from MHS individuals are more sensitive to 4–CmC than those from MHN, reflecting a 
greater Ca2+ turnover. The acidification response, however, was less pronounced than in muscle cells, presumably 
reflecting the lower expression of RyR1 in B–lymphocytes. Metabolic assays of B–lymphocytes might be a viable 
but less–invasive adjunct to IVCT for pre–screening in MHS susceptibility. The sensitivity and specificity of the 
4-CmC increased acidification rate resembles the range of the IVCT using only one test substance. Additional 
research is required to identify additional test substances for microphysiometry and to further elucidate the sen-
sitivity and specificity of the technique prior to potential clinical use. Nonetheless, this study provides the first 
evidence that a functional test approach using 20 ml human blood may discriminate between MHS and MHN 
individuals.
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